The impact of EGLN2 on pancreatic cancer glycolysis was assessed by using the Extracellular Flux Analyzer, and showed that overexpression of EGLN2 inhibited glycolytic capacity (Fig. 6f, g). Here, EGLN2 is linked to familial pancreatic carcinoma.